Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10037417 | 0.98 | TSHR (0.37) | HIF1ATSHRCYP2C19FAAHTRPV1 | |
| SCHEMBL10037412 | 0.94 | HIF1A (0.38) | HIF1ATSHRCYP2C19 | |
| SCHEMBL5792687 | 0.85 | CYP2C19 (0.33) | CYP2C19 | |
| SCHEMBL596917 | 0.82 | CYP2C19 (0.34) | TSHRCYP2C19 | |
| SCHEMBL596557 | 0.79 | CYP2C19 (0.33) | TSHRCYP2C19 | |
| SCHEMBL596129 | 0.79 | CYP2C19 (0.33) | TSHRCYP2C19 | |
| SCHEMBL9801192 | 0.78 | TSHR (0.37) | TSHR | |
| SCHEMBL9654521 | 0.77 | RYR2 (0.33) | TSHRCYP2C19 | |
| SCHEMBL596112 | 0.77 | CYP2C19 (0.34) | TSHRCYP2C19 | |
| Cyclohexane SCHEMBL28843662 | 0.74 | HIF1A (0.64) | HIF1ATSHRFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097728-B2 | Iminosugar compounds with antiflavirus activity | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097728-B2 | Iminosugar compounds with antiflavirus activity | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097728-B2 | Iminosugar compounds with antiflavirus activity | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-01-17 | — | — | US | disclosed |
| US-20090042268-A1 | IMINOSUGAR COMPOUNDS WITH ANTIFLAVIRUS ACTIVITY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-02-12 | — | — | US | disclosed |
| US-20090042268-A1 | IMINOSUGAR COMPOUNDS WITH ANTIFLAVIRUS ACTIVITY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-02-12 | — | — | US | disclosed |
| US-20090042268-A1 | IMINOSUGAR COMPOUNDS WITH ANTIFLAVIRUS ACTIVITY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042268-A1 | IMINOSUGAR COMPOUNDS WITH ANTIFLAVIRUS ACTIVITY | INSRR, RNASEL, AGL | HIF1A 3553/4885TSHR 3570/4885CYP2C19 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.